Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | $4.00 | Buy | B. Riley Securities |
| 10/14/2021 | $10.00 | Buy | B. Riley Securities |
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 million in Q3 2023Product gross margins decreased to 61%, compared to 72% in Q3 2023, reflecting the impact of a planned production slowdown to rebalance inve
Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack patients requiring surgerySuccessful MDSAP certification confirms compliance with Health Canada and U.S. FDA quality management system requirements, replacing FDA audit and inspection if requiredHealth Canada and U.S. FDA regulatory decisions expected in 2025 PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the submission of its DrugSorb™-ATR Medical Device Licen
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023. Ms. Bloch served as the Company's Chief Financial Officer for 10 years until her retirement in March 2023, when she became Interim CFO as a consultant. She resumed as Interim CFO after the investigation of, and mutual termination and release agreement with, former CFO
B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00
B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00
SC 13G/A - Cytosorbents Corp (0001175151) (Subject)
SC 13G - Cytosorbents Corp (0001175151) (Subject)
SC 13G - Cytosorbents Corp (0001175151) (Subject)
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 million in Q3 2023Product gross margins decreased to 61%, compared to 72% in Q3 2023, reflecting the impact of a planned production slowdown to rebalance inve
PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2024 operating and financial results after the market close on Thursday, November 7, 2024. CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. Webcast Details:Date: Thursday, November 7, 2024Time: 4:30 PM ETLive webcast link: https://edge.media-server.com/mmc/p/e9gv3iawConference ID: 9258825 Participant Dial-In:Participant Dial-in toll-free: (80
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by 10% and reduced operating loss by 48%Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestone PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results Total revenue for Q2 202
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
10-Q - Cytosorbents Corp (0001175151) (Filer)
8-K - Cytosorbents Corp (0001175151) (Filer)
8-K - Cytosorbents Corp (0001175151) (Filer)
CytoSorbents Corp (NASDAQ:CTSO) shares are trading higher by 21% to $0.85 during Tuesday’s session after the company entered into a new $20 million credit facility with Avenue Capital Group. The company says the funds will provide non-dilutive working capital to support the global CytoSorb® franchise in critical care and cardiac surgery, and aid in FDA and Health Canada applications for DrugSorb™-ATR. The credit agreement has a three-year term and includes an initial $15 million tranche, with $10 million available immediately and an additional $5 million contingent on FDA acceptance of the DrugSorb-ATR De Novo application. Meanwhile, a second $5 million tranche is available in lat
Proceeds from the facility are intended to provide non-dilutive working capital to support the Company's ongoing global CytoSorb® franchise in critical care and cardiac surgery that generated $32.2 million in trailing 12-month sales as of March 31, 2024, planned marketing applications to U.S. Food and Drug Administration (FDA) and Health Canada for DrugSorb™-ATR and initial launch and commercialization preparations if approved, and refinancing of existing Bridge Bank debt.